The FDA approved daraxonrasib, a twice-daily pill that can help advanced pancreatic cancer patients live a median of over 13 months, compared to less than 7 months on chemotherapy. It works by targeting KRAS, a mutated protein once thought impossible to drug. Pancreatic cancer kills over 50,000 Americans a year with brutal survival odds, so a treatment doubling life expectancy marks a genuine turning point for a disease long considered nearly hopeless.
No comments:
Post a Comment